Skip Navigation


International Immunology Advance Access originally published online on January 27, 2009
International Immunology 2009 21(3):269-282; doi:10.1093/intimm/dxn147
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
21/3/269    most recent
dxn147v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Ganesh, B. B.
Right arrow Articles by Prabhakar, B. S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ganesh, B. B.
Right arrow Articles by Prabhakar, B. S.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?


© The Japanese Society for Immunology. 2009. All rights reserved. For permissions, please e-mail: journals.permissions@oxfordjournals.org

GM-CSF-induced CD11c+CD8a—dendritic cells facilitate Foxp3+ and IL-10+ regulatory T cell expansion resulting in suppression of autoimmune thyroiditis

Balaji B. Ganesh1, Donald M. Cheatem1, Jian Rong Sheng1, Chenthamarakshan Vasu2 and Bellur S. Prabhakar1

1 Department of Microbiology and Immunology
2 Department of Surgery, College of Medicine, University of Illinois at Chicago, Chicago, IL 60612, USA

Correspondence to: B. S. Prabhakar; E-mail: bprabhak{at}uic.edu

GM-CSF plays an essential role in the differentiation of dendritic cells (DCs). Our studies have shown that GM-CSF treatment can induce semi-mature DCs and CD4+CD25+ regulatory T cells (Tregs) and suppress ongoing autoimmunity in mouse models. In this study, we examined the differences in the potential of GM-CSF to exert tolerogenic function on CD8a+ and CD8a– sub-populations of DCs in vivo. We show that GM-CSF modulates CD8a–, but not CD8a+ DCs in vivo, by inhibiting the surface expression of activation markers MHC II and CD80 and production of inflammatory cytokines such as IL-12 and IL-1β. Self-antigen [mouse thyroglobulin (mTg)] presentation by GM-CSF-exposed CD8a– DCs to T cells from mTg-primed mice induced a profound increase in the frequency of forkhead box P3 (FoxP3)-expressing T cells compared with antigen presentation by GM-CSF-exposed CD8a+ DCs and control CD8a+ and CD8a– DCs. This tolerogenic property of GM-CD8a– DCs was abrogated when IL-12 was added. GM-CSF-exposed CD8a– DCs could also induce secretion of significantly higher amounts of IL-10 by T cells from mTg-primed mice. Importantly, adoptive transfer of CD8a– DCs from GM-CSF-treated SCID mice, but not untreated mice, into wild-type CBA/J mice prevented the development of experimental autoimmune thyroiditis (EAT) in the recipient animals upon immunization with mTg. Collectively, our results show that GM-CSF renders CD8a– DCs tolerogenic, and these DCs induce Foxp3+ and IL-10+ Tregs.

Keywords: autoimmunity, dendritic cells, GM-CSF, regulatory T cells, thyroiditis, tolerance


Transmitting editor: C. Terhorst

Received 16 April 2008, accepted 17 December 2008.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.